Result card

  • TEC17: Is the technology rapidly changing / improving?
Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX )
B0017
English
No adaptation help available for this domain

Is the technology rapidly changing / improving?

Authors: Pseudo169 Pseudo169, Pseudo90 Pseudo90, Pseudo154 Pseudo154, Pseudo98 Pseudo98

Internal reviewers: Patricia Harrington, Michelle O'Neill, Leonor Varela

Free internet searches were used to develop this assessment element.

The technology itself is not characterised by a fast rate of development; the working principles of the tests have been known for a number of years and no breakthroughs are anticipated. However, given the research activities in the field of cancer genetics and genomics, it is likely that new applications of the same technology will be proposed in the future {19}.

Critical
Completely
Pseudo169 P et al. Result Card TEC17 In: Pseudo169 P et al. Description and technical characteristics of technology In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=113

References

  • {19}  Gwinn M, Grossniklaus DA, Yu W, Melillo S, Wulf A, Flome J, Dotson WD, Khoury MJ. Horizon scanning for new genomic tests. Genetics in Medicine 2011 13:2 (161–165).